ATHE vs DCGO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score limits bankruptcy risk assessment. Despite strong revenue growth of 80.90% YoY and a pristine balance sheet with zero debt and a current ratio of 12.98, the company is deeply unprofitable with a profit margin of -223.35% and negative ROE of -43.23%. Valuation metrics are extreme, with a Price/Book of 1038.03 and a negative Forward P/E of -4.49, suggesting significant overvaluation relative to book and earnings. While insider sentiment is moderately positive at 40/100 and analysts project a high target price of $12.00, the lack of profitability, inconsistent cash flow data, and weak technical trend (0/100) raise serious concerns about sustainability.
DCGO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
ATHE vs DCGO: Head-to-Head Comparison
This page compares Alterity Therapeutics Limited (ATHE) and DocGo Inc. (DCGO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.